Literature DB >> 23446333

Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study.

Uwe Siebert1, Johannes Wurm, Raffaella Matteucci Gothe, Marjan Arvandi, Stephan R Vavricka, Roland von Känel, Stefan Begré, Michael C Sulz, Christa Meyenberger, Markus Sagmeister.   

Abstract

BACKGROUND: Inflammatory bowel disease can decrease the quality of life and induce work disability. We sought to (1) identify and quantify the predictors of disease-specific work disability in patients with inflammatory bowel disease and (2) assess the suitability of using cross-sectional data to predict future outcomes, using the Swiss Inflammatory Bowel Disease Cohort Study data.
METHODS: A total of 1187 patients were enrolled and followed up for an average of 13 months. Predictors included patient and disease characteristics and drug utilization. Potential predictors were identified through an expert panel and published literature. We estimated adjusted effect estimates with 95% confidence intervals using logistic and zero-inflated Poisson regression.
RESULTS: Overall, 699 (58.9%) experienced Crohn's disease and 488 (41.1%) had ulcerative colitis. Most important predictors for temporary work disability in patients with Crohn's disease included gender, disease duration, disease activity, C-reactive protein level, smoking, depressive symptoms, fistulas, extraintestinal manifestations, and the use of immunosuppressants/steroids. Temporary work disability in patients with ulcerative colitis was associated with age, disease duration, disease activity, and the use of steroids/antibiotics. In all patients, disease activity emerged as the only predictor of permanent work disability. Comparing data at enrollment versus follow-up yielded substantial differences regarding disability and predictors, with follow-up data showing greater predictor effects.
CONCLUSIONS: We identified predictors of work disability in patients with Crohn's disease and ulcerative colitis. Our findings can help in forecasting these disease courses and guide the choice of appropriate measures to prevent adverse outcomes. Comparing cross-sectional and longitudinal data showed that the conduction of cohort studies is inevitable for the examination of disability.

Entities:  

Mesh:

Year:  2013        PMID: 23446333     DOI: 10.1097/MIB.0b013e31827f278e

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  16 in total

1.  Determinants of Healthcare Utilization Among Veterans with Inflammatory Bowel Disease.

Authors:  Mimi C Tan; Hashem B El-Serag; Jason K Hou
Journal:  Dig Dis Sci       Date:  2016-12-23       Impact factor: 3.199

2.  The socio-economic impact of work disability due to inflammatory bowel disease in Brazil.

Authors:  Renata de S B Fróes; Ana Teresa Pugas Carvalho; Antonio Jose de V Carneiro; Adriana Maria Hilu de Barros Moreira; Jessica P L Moreira; Ronir R Luiz; Heitor S de Souza
Journal:  Eur J Health Econ       Date:  2017-05-18

3.  Multidisciplinary teams as standard of care in inflammatory bowel disease.

Authors:  Subrata Ghosh
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

Review 4.  Impact of inflammatory bowel disease on disability.

Authors:  Katharina Büsch; Amnon Sonnenberg; Nick Bansback
Journal:  Curr Gastroenterol Rep       Date:  2014-10

Review 5.  Preventing disability in inflammatory bowel disease.

Authors:  Patrick B Allen; Corinne Gower-Rousseau; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

6.  Examining Psychosocial Mechanisms of Pain-Related Disability in Inflammatory Bowel Disease.

Authors:  Katherine M Fretz; Dean A Tripp; Laura Katz; Mark Ropeleski; Michael J Beyak
Journal:  J Clin Psychol Med Settings       Date:  2020-03

7.  UEG Week 2020 Poster Presentations.

Authors: 
Journal:  United European Gastroenterol J       Date:  2020-10       Impact factor: 4.623

8.  Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Authors:  Michael D Mandel; Mandel D Michael; Anita Bálint; Barbara D Lovász; László Gulácsi; Bálint Strbák; Petra A Golovics; Klaudia Farkas; Zsuzsanna Kürti; Blanka K Szilágyi; Anna Mohás; Tamás Molnár; Péter L Lakatos
Journal:  Eur J Health Econ       Date:  2014-05-16

9.  The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.

Authors:  Aaron Yarlas; Linnette Yen; Paul Hodgkins
Journal:  Qual Life Res       Date:  2014-09-06       Impact factor: 4.147

10.  Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account.

Authors:  Jonas Zeitz; Melike Ak; Séverine Müller-Mottet; Sylvie Scharl; Luc Biedermann; Nicolas Fournier; Pascal Frei; Valerie Pittet; Michael Scharl; Michael Fried; Gerhard Rogler; Stephan Vavricka
Journal:  PLoS One       Date:  2016-06-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.